

## FORM 7

### **MONTHLY PROGRESS REPORT**

Name of Listed Issuer: BioNxt Solutions Inc. (the “**Issuer**”)

Trading Symbol: BNXT

Number of Outstanding Listed Securities: 93,417,873 common shares

Date: February 3, 2023 (for the month ended January 31, 2023)

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

The Issuer is a diversified bioscience accelerator that continues to focus on next-generation drug delivery, diagnostic, and new active pharmaceutical ingredient investment opportunities, including, precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. The Issuer has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.

2. Provide a general overview and discussion of the activities of management.

During the month of January, 2023, management’s principal activities consisted of, but were not limited to general management and administrative matters of the Issuer and its subsidiaries.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

None.

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

None.

5. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture

agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

None.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

None.

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from, or the disposition was to a Related Person of the Issuer and provide details of the relationship.

None.

8. Describe the acquisition of new customers or loss of customers.

None.

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

None.

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

None.

11. Report on any labour disputes and resolutions of those disputes if applicable.

None.

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

None.

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

None.

14. Provide details of any securities issued and options or warrants granted.

Security	Number Issued	Details of Issuance	Use of Proceeds <sup>(1)</sup>
Common Shares	2,208,000	Exercise of share purchase warrants at \$0.50 per share	\$1,104,000 – general working capital

(1) State aggregate proceeds and intended allocation of proceeds.

15. Provide details of any loans to or by Related Persons.

None.

16. Provide details of any changes in directors, officers or committee members.

There were no changes in directors, officers or committee members during the month of January, 2023.

As of the date hereof, the following are the current directors and officers of the Issuer:

Hugh Rogers – Chief Executive Officer and Director

Wolfgang Probst –Director

Raimar Löbenberg – Director

Per S. Thoresen – Director

Peter Damouni – Director

P. Joseph Meagher – Chief Financial Officer and Corporate Secretary

As of the date hereof, the following are members of the Issuer's audit committee:

Hugh Rogers

Raimar Löbenberg

Wolfgang Probst

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The trends and risks which are likely to impact the Issuer are set out in the section entitled "Risks and Uncertainties" in the Issuer's Management's Discussion and Analysis for the quarter ended September 30, 2022, and filed under the Issuer's profile on SEDAR ([www.sedar.com](http://www.sedar.com)).

## Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.

2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated January 5, 2023.

Hugh Rogers  
Name of Director or Senior Officer

/s/Hugh Rogers  
Signature

Chief Executive Officer  
Official Capacity

<b>Issuer Details</b>	For Month End	Date of Report
Name of Issuer		YY/MM/D
BioNxt Solutions Inc.	January, 2023	23/02/03
Issuer Address		
#270 – 1820 Fir Street		
City/Province/Postal Code	Issuer Fax No. (   )	Issuer Telephone No.
Vancouver, BC, V6J 3B1		(780) 818-6422
Contact Name	Contact Position	Contact Telephone No.
Hugh Rogers	CEO	(780) 818-6422
Contact Email Address	Web Site Address	
<a href="mailto:info@bionxt.com">info@bionxt.com</a>	<a href="http://www.bionxt.com">www.bionxt.com</a>	